Trials / Completed
CompletedNCT05345366
The Correlation Between CITED2 and Collateral Circulation in Acute Ischemic Stroke
The Impact of CITED2 on Collateral Circulation and Early Neurological Functional Outcome for Ischemic Stroke by Critically Regulating HIF-1α-VEGF Pathway
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 130 (actual)
- Sponsor
- Zhujiang Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the collateral circulation of acute ischemic stroke (AIS) mainly depends on the imaging examination. At present, there is no effective and sensitive biomarker for collateral circulation. Thus, the research objective was to evaluate the predicting role of the CBP/P300-interacting transactivator with Glu/Asp-rich C-terminal domain 2 Ratio (CITED2) from peripheral blood mononuclear cells in the collateral circulation of AIS. We classified the AIS patients into two groups (the good collateral group and the poor collateral group) by DWI-ASPECTS score. The western blot was applied to test the protein expression of vascular endothelial growth factor (VEGF) and CITED2. Then, we collected other clinical data. Binary logistic regression analysis between collateral circulation and clinical data was performed. Finally, Receiver operating characteristic (ROC) curve analysis was used to explore the predictive value of the CITED2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | non-applicable | non-applicable |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2021-11-30
- Completion
- 2024-03-01
- First posted
- 2022-04-25
- Last updated
- 2024-06-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05345366. Inclusion in this directory is not an endorsement.